Conferences

Frederick Locke, MD, on Further CAR T Research

June 16th 2022

The vice-chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center discussed more work to be done with CAR T-cell therapies.

Frederick Locke, MD, on the Impact Potential of CAR T-Cell Therapies in Hematologic Malignancies

June 9th 2022

The vice-chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center discussed positive data seen with tisa-cel, liso-cel, ide-cel, cilta-cel, and brexu-cel.

CARsgen Therapeutics’ CT041 Shows Promise in Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

June 8th 2022

The chimeric antigen receptor-modified autologous T cells targeting CLDN18.2 had a manageable safety/tolerability profile and promising efficacy.

Gamma Delta CAR T-Cell Therapy Shows Promising Responses in B-Cell Malignancies

June 8th 2022

100% overall response and complete response rates were seen in patients treated with prior CD19 CAR T-cell therapy.

NY-ESO-1 TCR T-Cell Therapy Shows Clinical Activity in Soft Tissue Sarcoma

June 8th 2022

Overall response rate was 41.7% and median progression free survival was 7.2 months.

Axi-Cel Superior to SOC in Elderly Patients with Diffuse Large B-Cell Lymphoma

June 7th 2022

Jason Westin, MD, FACP, leader, DLBCL research team, MD Anderson Cancer Center, discussed results from the ZUMA-7 trial at ASCO 2022.

Synthetic Binding Domain CAR T Therapy Yields 100% ORR in R/R Multiple Myeloma

June 7th 2022

69% of patients followed up for at least 1 year continue to have an ongoing response.

STRIVE-02: First-in-Human B7H3 CAR T-Cells for Pediatric Patients With Relapsed/Refractory Solid Tumors

June 6th 2022

Three of the 9 patients who received the infusion demonstrated best overall response of Stable Disease, and investigators determined dose level 2 to be the biologically effective dose.

Cilta-Cel Yields 100% ORR in Patients With Early Relapse of Multiple Myeloma

June 6th 2022

Niels van de Donk, MD, PhD, professor, Amsterdam University Medical Centers, discussed positive findings from cohort B of the CARTITUDE-2 study.

Early Bone Marrow MRD Status May Determine CAR-T Therapy Response in Myeloma

June 6th 2022

Regardless of bone marrow cellularity, bone marrow minimal residual disease (MRD) negativity at month 1 correlated with deep response and prolonged PFS.